What Is Ornipressin? Definition and What Research Reports

Definition

Ornipressin is a synthetic analogue of vasopressin (antidiuretic hormone) in which the arginine residue at position 8 of the natural nonapeptide is replaced by the amino acid ornithine — hence its chemical name, 8-ornithine-vasopressin. Like vasopressin, it is a cyclic nine–amino-acid peptide with an intramolecular disulfide bridge. In the published literature it is characterised as a vasoconstrictor peptide that acts predominantly at vascular (V1-type) vasopressin receptors rather than at the renal water-handling (V2-type) receptors, and a dose-response study in human skin reported that ornipressin produced graded cutaneous vasoconstriction across the range tested (PMID 7917739). Ornipressin has been described in the European clinical literature under the trade name POR 8, principally as an injectable agent used locally to reduce bleeding in surgical fields; it is not an FDA-approved medicine in the United States. This page is for educational purposes only and is not medical advice; consult a licensed physician for any question about medical treatment.

What Class of Molecule Is It, and Where Does the Term Come From?

Ornipressin belongs to the vasopressin analogue family — a group of small, structurally related peptides derived from the natural neurohypophyseal hormones vasopressin and oxytocin. Chemists produced these analogues by substituting individual residues of the parent hormone in order to shift the balance between vasoconstrictor (V1) and antidiuretic (V2) activity, or to change how quickly the peptide is cleared. Ornipressin sits on the vasoconstrictor-weighted side of that family; other well-known members of the broader group include desmopressin (V2-weighted) and terlipressin (a triglycyl prodrug of lysine-vasopressin).

The word itself is a straightforward contraction: orni- for the ornithine substitution plus -pressin, the suffix used for pressor (blood-pressure–raising) vasopressin derivatives. Because ornipressin is a defined synthetic peptide rather than an extract, papers usually refer to it by name alone, with older literature sometimes using "POR 8" or "8-ornithine-vasopressin" interchangeably.

How the Term Is Used in Peptide Research

In research writing, "ornipressin" appears in three recognisable contexts:

• As a comparator or reference vasoconstrictor. Because its receptor preference and potency profile were characterised in human volunteers, ornipressin is sometimes cited when authors discuss how vasopressin analogues differ from one another.
• As an infused systemic agent in liver disease studies. Much of the clinical literature examines intravenous ornipressin in patients with decompensated cirrhosis and functional renal failure, including the condition now described as hepatorenal syndrome.
• As a locally infiltrated haemostatic agent in surgery. Here it is injected into the operative field rather than given systemically, with bleeding volume as the measured outcome.

The term is definitional and pharmacological; it does not denote a research "category" of compounds the way words like "secretagogue" or "GLP-1 analogue" do. Ornipressin is one specific molecule.

What the Published Literature Reports

Renal function in decompensated cirrhosis

The largest body of ornipressin research concerns kidney function in advanced liver disease. A 1991 study in Gastroenterology examined intravenous ornipressin in patients with decompensated cirrhosis and functional renal failure and reported improvements in renal haemodynamics together with changes in atrial natriuretic factor (PMID 1832407). An earlier single-patient report in Gut described enhancement of renal function with ornipressin in a patient with decompensated cirrhosis (PMID 4085913).

Two later papers from the same research area examined longer courses. Researchers reported that prolonged administration of ornipressin combined with plasma volume expansion was associated with reversal of hepatorenal syndrome in treated patients, while ischaemic complications occurred in others (PMID 9425914). A 1999 Hepatology paper described long-term therapy and retreatment of hepatorenal syndrome type 1 using ornipressin together with dopamine, reporting improvement in renal function during treatment and on retreatment after recurrence (PMID 10498636). These were small, uncontrolled clinical investigations in a severely ill population, not large randomised trials.

Local haemostasis in surgery

A randomised controlled trial published in the International Urogynecology Journal compared vaginal infiltration with ornipressin against saline during vaginal prolapse surgery and reported lower intraoperative blood loss in the ornipressin group (PMID 26294207). This line of work treats ornipressin as a locally acting vasoconstrictor injected into tissue, which is conceptually different from the systemic infusion studies above.

Dose-response characterisation

A British Journal of Anaesthesia study set out the dose-response relation for ornipressin with regard to vasoconstriction in human skin, and the study reported a graded vasoconstrictor response, providing the human potency reference that later papers cite (PMID 7917739).

Summary Table of the Cited Literature

Ornipressin Adverse Events: What Studies Report

Because ornipressin is a vasoconstrictor, the adverse events described in the literature are predominantly ischaemic. In the hepatorenal syndrome work, researchers reported that ischaemic complications arose in some patients receiving prolonged ornipressin together with plasma volume expansion, leading to treatment being stopped in those cases (PMID 9425914). The later long-term study of ornipressin with dopamine in hepatorenal syndrome type 1 similarly discussed tolerability alongside the renal outcomes it reported (PMID 10498636). The surgical trial evaluated ornipressin infiltration against saline in a controlled setting and reported blood-loss outcomes for both groups (PMID 26294207). Readers should note that these were small studies in specific clinical populations, and that the safety picture from a handful of hospital-based investigations is not a general safety profile.

Limitations of the Evidence Base

1. Small samples. The cirrhosis and hepatorenal syndrome literature consists of case reports and small clinical series rather than large randomised trials (PMID 4085913, PMID 1832407).
2. Age of the literature. Most systemic studies date from the 1980s and 1990s, and clinical practice in hepatorenal syndrome has shifted toward other vasopressin analogues since then.
3. Two different exposure routes. Findings from local tissue infiltration during surgery (PMID 26294207) do not transfer to systemic intravenous infusion, and vice versa.
4. No long-term outcome data. The cited papers report short-horizon physiological and surgical endpoints, not long-term outcomes.

Related Glossary Terms

• Vasopressin (ADH) — the natural nonapeptide hormone from which ornipressin is derived.
• Vasopressin analogue — the structural family that includes ornipressin, desmopressin and terlipressin.
• V1 receptor — the vascular vasopressin receptor subtype associated with vasoconstriction.
• Hepatorenal syndrome — the kidney failure syndrome of advanced liver disease in which much of the ornipressin literature was generated.

This entry is definitional and summarises published findings only. It does not describe how ornipressin is administered, and no protocol, quantity or schedule should be inferred from it. This page is for educational purposes only and is not medical advice; consult a licensed physician with questions about any medical condition or treatment.

References

• Ornipressin in the treatment of functional renal failure in decompensated liver cirrhosis. Effects on renal hemodynamics and atrial natriuretic factor (Gastroenterology, 1991)
• Effect of vaginal infiltration with ornipressin or saline on intraoperative blood loss during vaginal prolapse surgery: a randomised controlled trial (International Urogynecology Journal, 2016)
• Reversibility of hepatorenal syndrome by prolonged administration of ornipressin and plasma volume expansion (Hepatology, 1998)
• Dose-response relation of ornipressin with regard to vasoconstriction in human skin (British Journal of Anaesthesia, 1994)
• Long-term therapy and retreatment of hepatorenal syndrome type 1 with ornipressin and dopamine (Hepatology, 1999)
• Enhancement of renal function with ornipressin in a patient with decompensated cirrhosis (Gut, 1985)